Trials / Completed
CompletedNCT02828319
Clinical Study of Z-213 in Subjects With Iron-deficiency Anemia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 39 (actual)
- Sponsor
- Zeria Pharmaceutical · Industry
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
To confirm the safety and efficacy of Z-213 until 12 weeks after start of Z-213 administration in patients with iron deficiency Anemia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Z-213 | The total iron dosage is calculated based on hemoglobin value and the patients' weight, IV on day 1, 8 and 15 (if needed) |
Timeline
- Start date
- 2016-07-01
- Primary completion
- 2017-05-01
- Completion
- 2017-12-01
- First posted
- 2016-07-11
- Last updated
- 2018-03-06
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02828319. Inclusion in this directory is not an endorsement.